Zhidong Gao

Microsatellite-stable/proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC) is characterized by a cold tumor microenvironment, with limited CD8⁺ T cell infiltration and poor responsiveness to immune checkpoint inhibitors (ICIs). Here, using an in vivo CRISPR/Cas9 screen in a CMT93 cell-derived murine tumor model, we identify Arid3b as a key negative regulator of CD8⁺ T cell infiltration and antitumor activity. Genetic ablation of Arid3b in CD8⁺ T cells significantly enhances their intratumoral accumulation and promotes robust tumor control. Mechanistically, Arid3b deficiency upregulates Runx3 , driving a tissue-resident memory-like phenotype and effector function. Notably, the benefits conferred by Arid3b deficiency are abrogated upon Runx3 deletion, indicating a RUNX3-dependent mechanism. Together, targeting ARID3B could offer a promising strategy to reshape the tumor microenvironment and sensitize MSS CRC to immunotherapy.

The application of immunoscore (IS) in non-metastatic colorectal cancer has been validated. We performed a meta-analysis to evaluate the prognostic value o

Gastric bronchogenic cyst constitutes a rare form of ectopic bronchogenic cyst, with an estimated incidence of less than 1 in 68,000 to 1 in 42,000. This s

Supplementary Figure S5. RFS in primary localized gastric GIST excluding SDH-deficient cases.

Mutational analysis guides therapeutic decision-making for patients with advanced-stage gastrointestinal stromal tumors (GISTs). A total of 491 patients wi

Supplementary Figure 1. Traditional risk stratification in primary gastric and small bowel GIST. Primary gastric (A-C) and small bowel (D-F) GISTs localized at diagnosis without prior neoadjuvant treatment are risk stratified into low, moderate, and high risk groups based on site, tumor size and mitotic rate using the Miettinen (also includes very low risk) (A, D), Fletcher (B, E) and Joensuu (C, F) risk stratification schemes (Miettinen 2006, Fletcher 2002, Joensuu 2008). Recurrence-free survival for patients in each of these risk groups is represented by Kaplan-Meier curves (global log-rank P) for all primary localized cases.

Supplementary Figure S4. RFS in primary localized gastric (A) and small bowel (B) GISTs by types of primary KIT and PDGFRA mutations [del: deletion; ex: exon; INS: insertion; PM: point mutation].

Supplementary Figure 3. Genomic risk groups versus tumor size and mitotic rate.

Supplementary Figure 2. Multivariate Cox regression survival analysis for primary gastric and small bowel GISTs represented by forest plots.